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ABSTRACT
Introduction: Helicobacter pylori eradication has become increasingly difficult as resistances to several antibiotics develop. We aimed 
to compare Helicobacter pylori eradication rates between triple therapy and sequential therapy in a naive Portuguese population.
Material and Methods: Prospective randomized trial including consecutive patients referred for first-line Helicobacter pylori eradication 
treatment. Exclusion criteria: previous gastric surgery/neoplasia, pregnancy/lactancy, allergy to any of the drugs. The compared 
eradication regimens were triple therapy (pantoprazol, amoxicillin and clarithromycin 12/12 hours, 14 days) and sequential therapy 
(pantoprazol 12/12 hours for 10 days, amoxicillin 12/12 hours for days 1 - 5 and clarithromycin plus metronidazol 12/12 hours during 
days 6 - 10). Eradication success was confirmed with urea breath test. Statistical analysis was performed with SPSS v21.0 and a 
p-value < 0.05 was considered statistically significant.
Results: Included 60 patients, 39 (65%) female with mean age 52 years (SD ± 14.3). Treatment groups were homogeneous for 
gender, age, indication for treatment and smoking status. No statistical differences were encountered between sequential and triple 
therapy eradication rates (86.2% vs 77.4%, p = 0.379), global eradication rate was 82%. Tobacco consumption was associated with a 
significantly lower eradication success (54.5 vs 87.8%, p = 0.022).
Discussion: In this randomized controlled trial in a naive Portuguese population, we found a satisfactory global Helicobacter pylori 
eradication rate of 82%, with no statistical differences observed in the efficacy of the treatment between triple and sequential regimens. 
Conclusion: These results support the use of either therapy for the first-line eradication of Helicobacter pylori.
Keywords: Anti-Bacterial Agents; Drug Therapy, Combination; Helicobacter Infections/drug therapy; Helicobacter pylori; Portugal; 
Stomach Neoplasms
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RESUMO
Introdução: A erradicação do Helicobacter pylori tem adquirido dificuldade progressiva, devido às resistências para os antibióticos 
utilizados. Pretendemos comparar a eficácia na erradicação do Helicobacter pylori entre o tratamento triplo e sequencial numa popu-
lação portuguesa naive.
Material e Métodos: Trabalho prospectivo randomizado incluindo doentes consecutivos submetidos a primeiro tratamento de er-
radicação do Helicobacter pylori. Critérios de exclusão: cirurgia/neoplasia gástrica prévias, gravidez/aleitamento, alergia a algum dos 
fármacos. Os esquemas utilizados foram o tratamento triplo (pantoprazol, amoxicilina claritromicina 12/12 horas, 14 dias) e tratamento 
sequencial (pantoprazol 12/12 horas durante 10 dias, amoxicilina 12/12 horas nos dias 1 - 5 e claritromicina e metronidazol 12/12 horas 
nos dias 6 - 10). A eficácia da erradicação foi confirmada com um teste respiratório da ureia. A análise estatística foi efectuada com o 
SPSS v21.0 e um valor de p < 0,05 foi considerado estatisticamente significativo.
Resultados: Incluídos 60 doentes, 39 (65%) mulheres, idade média 52 anos (DP ± 14,3). Os grupos de tratamento foram homogéneos 
para as variáveis sexo, idade, indicação para tratamento e tabagismo. Não foram observadas diferenças estatisticamente significativas 
na eficácia de erradicação do Helicobacter pylori entre o tratamento triplo e sequencial (86,2% vs 77,4%, p = 0,379), com uma taxa 
global de erradicação de 82%. O tabagismo foi associado significativamente a uma menor eficácia de erradicação (54,5 vs 87,8%, 
p = 0,022).
Discussão: Neste ensaio clínico randomizado numa população portuguesa naive, encontrámos uma eficácia global de erradicacão do 
Helicobacter pylori de 82%, sem diferenças estatisticamente significativas entre o tratamento triplo e o tratamento sequencial. 
Conclusão: Estes resultados reforçam a possibilidade de utilizar qualquer um destes tratamentos como primeira linha na erradicação 
do Helicobacter pylori.
Palavras-chave: Farmacoterapia Combinada; Helicobacter pylori; Infecções por Helicobacter/tratamento; Neoplasias do Estômago; 
Portugal
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INTRODUCTION
 Helicobacter pylori (HP) is the most prevalent human 
infectious pathogen,1 affecting more than 50% of the world 
adult population.1 The prevalence of HP infection varies 
widely across populations,2 depending on geographical and 
demographic factors - in Northern Europe the prevalence is 
reported to be below 40%,2 in Japan 70%,2 and in Portugal 
the prevalence of HP was 90% two decades ago,3 and 84% 
in a recent study by Bastos et al.4
 HP is a known carcinogenic agent to humans,5 responsi-
ble for 660 000 cases of cancer worldwide6 - more than 
75% of all gastric cancers,6 half of the infection-associated 
cancers in developed countries.6 HP is also associated with 
gastrointestinal non-malignant diseases, such as functional 
dyspepsia,7 gastritis and peptic ulcer disease,8 as well as 
with iron-deficient anemia,9 idiopathic thrombocytopenic 
purpura10 and risk of cardiovascular events.11 In fact, it has 
been demonstrated that HP eradication not only improves 
most non-malignant associated diseases, but may also 
reduce the future risk of gastric cancer by up to 80%,12 and 
a recent meta-analysis suggests that population screening 
and eradication of HP strategy is cost-effective.13
 According to the Maastricht IV Consensus on HP 
management,1 clarithromycin resistance in each region 
should determine the most adequate first-line treatment 
for HP eradication - in regions where the clarithromycin 
resistance is inferior to 15% - 20%, the triple therapy (TT), 
containing a proton-pump inhibitor (PPI), amoxicillin and 
clarithromycin, is adequate, whereas if the resistance to 
clarithromycin is superior to this threshold, other treatment 
options, such as the sequential treatment (ST) (PPI plus 
amoxicillin followed by PPI, clarithromycin and an imidazole) 
could be preferable.
 In Europe, an increase in clarithromycin resistance from 
10 to 17.5%14 has been witnessed in the last decade, and 
the latest data from central Portugal indicates a resistance 
rate of 21.4%.15 
 A meta-analysis by Gatta et al,16 comparing 14-day TT 
versus ST, found no differences in HP eradication rate, but 
prospective Western European studies comparing both 
strategies are currently lacking, and the most adequate 
first-line eradication regimen for HP in Portugal has not yet 
been determined. 
 We aimed to compare HP eradication rates between 14-
day TT and 10-day ST in a naive Portuguese population, as 
well as to analyse other factors associated with a reduced 
treatment efficacy.
MATERIAL AND METHODS
 We performed a prospective, unicentric, open-label 
randomized trial in the Gastroenterology department of our 
institution.
 Inclusion criteria included outpatients with over 18 
years with newly diagnosed HP infection. The diagnosis 
of HP infection was performed by immunohistochemical 
staining in gastric biopsy specimens performed during a 
recent esophagogastroduodenoscopy (≤ 6 months). The 
enrollment period was 12 months.
 Patients were excluded if they had been previously 
treated for HP, had a previous gastric surgery or gastric 
cancer, were diagnosed with severe medical illnesses, such 
as liver failure or heart failure, were treated with antibiotics in 
the four weeks before enrollment or between the diagnosis 
and enrollment, had a known allergy to any of the treatment 
drugs, or were pregnant or lactating women.
 Patients’ demographic variables (gender, age), co-
morbidities, current medication, indication for eradication 
and smoking status were registered.
 Sample size was calculated, based on both previous 
Portuguese15 and European studies,1 for a 95% confidence 
interval and power of 0.8, to be n = 59.
 Randomization was performed in blocks of 10, using 
opaque envelopes kept by an independent researcher, and 
distributed to the investigators after an informed consent for 
study investigation was given by the patients.
 Patients were randomized to either TT (pantoprazol 40 
mg, amoxicillin 1000 mg and clarithromycin 500 mg 12/12 
hours for 14 days) and ST (pantoprazol 40 mg 12/12 hours 
for 10 days, amoxicillin 1000 mg 12/12 hours during days 
1 - 5 and clarithromycin 500 mg 12/12 hours, metronidazol 
500 mg 12/12 hours during days 6 - 10). 
 Drug compliance was confirmed through self-report by 
direct patient questioning, and noncompliance was defined 
as failure to take at least 80% of the prescribed treatment 
regimen. Side-effects of medication were recorded, as well 
as the need to discontinue treatment for major side-effects 
or allergies.
 Eradication success was assessed by a laboratorial 
technician blinded to the treatment allocation, through 
13C-Urea Breath Test (13C-UBT), performed 4 - 6 weeks after 
treatment termination, and PPI suspension was mandatory 
for the two weeks previous to the test. 
 Per protocol (PP) and modified intention to treat analysis 
(MITT) - patients receiving at least one dose of treatment 
and with an available 13C-UBT result - was performed.
 Secondary analysis of incidence of side-effects, 
treatment discontinuation, drug compliance and individual 
factors associated with decreased eradication success was 
performed.
 Statistical analysis was performed using SPSS 21.1™ 
(WinWrap Basics™), through univariate analysis, using 
independent-samples t test for continuous variables and 
the chi-square test for categorical variables. Statistical 
significance was defined for p-value < 0.05, and quantitative 
variables were presented as mean ± standard deviation 
(SD).
 This study was conducted in accordance with the 
principles of the Declaration of Helsinki, ICH Guidelines for 
Good Clinical Practice and in full conformity with relevant 
regulations. Patients provided written informed consent for 
study participation. The study protocol was approved by the 
local ethics committee.
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RESULTS
 From January to December 2014, 63 patients fulfilled 
the inclusion criteria and were randomized (32 to TT, 31 
to ST); three patients were lost to follow-up and failed to 
return to 13C-UBT, and were excluded from the MITT and PP 
analysis. No patient refused to participate, and no allergies 
were documented during the study, resulting in 31 patients 
in the TT group and 29 patients in the ST group.
 Of the remaining 60 patients, 39 (65%) were female 
with mean age 52 years (SD ± 14.3). Chief indications 
for HP eradication were functional dyspepsia (41.7%), 
premalignant gastric lesions - extensive atrophic gastritis 
or intestinal metaplasia, low grade dysplasia - (23.3%) 
and peptic ulcer disease (13.3%), while unexplained iron-
deficient anemia was the indication in 10.0% of the cases, 
familial history of gastric cancer in 6.7% and hyperplastic 
polyps in 5.0% of the patients. Smoking status was positive 
for 18.3% of the patients, while 81.7% were non-smokers. 
Clinical characteristics of all patients, TT group and ST 
group are summarized on Table 1. TT and ST groups were 
homogeneous for gender, age, indication for treatment, and 
smoking status. 
 No statistical differences were encountered between ST 
and TT either on PP (85.2% vs 76.7%, p = 0.416) or MITT 
(86.2% vs 77.4%, p = 0.379) analysis, global eradication 
rate was 80.7% in the PP and 81.7 in the MITT analysis.
 Side-effects were reported in 12 (20.0%) patients (six in 
each treatment arm), most commonly dyspepsia, diarrhea 
and dysgeusia - Table 2. Only three patients (5.0%) were 
non-compliant, two on the ST group and one on the TT 
group; in one patient in the TT group the treatment was 
interrupted after 11 days for nausea and vomiting, and 
in two patients in the ST group, noncompliance resulted 
from complaints of diarrhea and dyspepsia, respectively - 
remarkably, eradication was successful in the three patients.
 Patient demographic factors, smoking status, indica-
tions for treatment and treatment compliance were 
analyzed to assess their impact on treatment outcome. 
Positive smoking status was associated with a significantly 
lower eradication success (54.5 vs 87.8%, p = 0.022); age, 
gender, indication for treatment and compliance status were 
not associated with an impact on treatment success.
DISCUSSION 
 The worldwide health burden of HP is a consequence 
of its high prevalence1,2,4 together with a significant number 
of associated diseases, mainly gastric adenocarcinoma, 
MALT lymphoma6 and peptic ulcer disease.8 
 In the last decades, a decreasing trend in prevalence of 
HP across the world was observed, declining to 20% - 40% 
in the United States of America17 and less than 30% in some 
European countries.2 Nevertheless, in Southern Europe the 
prevalence of HP is still high, and in Portugal no decrease 
was observed in the past 20 years,3,18 currently 84%4 and 
resulting in one of the highest gastric cancer mortality rates 
in Europe.18
 In 2012, the Maastricht IV Report consensus considered 
the standard TT to be an adequate first-line treatment for 
regions where clarithromycin resistance rates were inferior 
to 15% - 20%,1 but should be abandoned in favor of other 
regimens in regions of higher resistance prevalence. The 
rate of clarithromycin resistance in Portugal has most 
recently been shown to be 21.4%15 in study including 
patients from central Portugal, but significant variability 
within the country has been observed, ranging from 14.6% 
to 33%.14,19,20
 In our work, the global HP eradication rate in Portuguese 
naive patients from a Northern region was over 80%, and no 
significant differences in efficacy were observed between 
14-day TT and 10-day ST, either on PP (85.2% vs 76.7%, 
p = 0.416) or MITT (86.2% vs 77.4%, p = 0.379)  analysis.
 These results are comparable to the ones reported 
Table 1 - Patients’ sociodemographic characteristics
All patients
(n = 60)
TT group
(n = 31)
ST group
(n = 29) p
Female (%) 65.0 64.5 65.5 0.935 
Age, years (mean ± SD) 53 ± 14 49.8 ± 14.3 48.1 ± 13.7 0.868 
Smoking status 
     Smokers (%) 
     Non-smokers (%)
18.3
81.7 
13.8 
86.2 
22.6 
77.4 
0.379 
Indication for eradication 
     Functional dyspepsia (%) 
     Peptic ulcer disease (%) 
     Pre-malignant gastric lesions (%)
     Other (%) 
41.7
13.3
23.3
21.7 
41.9 
12.9 
29.0
16.2 
41.4 
13.8
17.2
27.8 
0.714
TT: Triple therapy; ST: Sequential therapy 
Table 2 - Side-effects of medication
TT group 
(n = 31) 
ST group 
(n = 29) 
  Any, n (%) 6 (19.3) 6 (20.7) 
  Dyspepsia, n (%) 2 (6.4) 4 (13.7) 
  Nausea / vomiting, n (%) 1 (3.2) 0 (0) 
  Diarrhea, n (%) 3 (9.6) 2 (6.8) 
  Dysgeusia, n (%) 0 (0) 1 (3.4) 
TT: Triple therapy; ST: Sequential therapy 
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by two recent multicentre trials involving naive patients: 
a Taiwanese trial by Liou et al,21 observed no significant 
differences between 10-day ST (87.0%) and 14-day TT 
(82.3%) eradication rates, and Greenberg et al22 conducted 
a multicentre study including several countries in South 
America, reporting no advantages in the eradication rate 
when using ST (76.5%) compared to 14-day TT (82.6%) - 
crucially, a study developed in countries with clarithromycin 
resistance rates superior to 20%.23 
 In a meta-analysis from Gatta et al,16 ST was superior to 
7-day and 10-day TT, but no advantage of ST was observed 
if TT was prolonged for 14 days (eradication rates 80.8% 
vs 81.3%, respectively), reflecting an improvement between 
5.0% and 9.8%1,16 in TT eradication rates with a 14-day 
course, and these results were replicated subsequently in 
another meta-analysis by Feng et al.24 Prospective Western 
European studies directly comparing 14-day TT with 10-day 
ST are currently lacking.
 In Portugal, Cerqueira et al20 reported 14-day TT 
eradication rates of 58.6% (ITT) and 62.9% (PP) in obese 
patients undergoing bypass surgery, and Almeida et al15 
observed eradication rates of 68.9% (ITT) and 68.8% 
(PP) with the same regimen in a population-based study. 
These contrasting results, reflecting a wide variation in 
eradication rates in the same country, probably reflect 
clarithromycin resistance variability across different regional 
populations.14,15,19
 Newer treatment options, such as concomitant25,26 (TT 
plus metronidazole), hybrid27,28 (ST, but with amoxicillin 
added during the second half of the regimen) and dual29 
(high dose PPI plus amoxicillin, four doses daily) treatment 
have been developed, in order to achieve eradication rates 
> 90%, as defended by Graham et al,30 and have shown 
superior eradication rates compared to TT, but in most of 
them, TT duration was inferior to 14 days.26,27,29 Regarding 
ST, a recent meta-analysis comparing it with hybrid and 
concomitant therapies showed no efficacy advantage in 
the newer treatment strategies.31 Bismuth-based regimens, 
advocated in the Maastricht IV Consensus as a first-
line treatment option in regions with high clarithromycin 
resistance,1 has shown favorable results,32 but bismuth 
is not widely available in many European countries, in 
particular in Portugal. Levofloxacin-based treatments have 
shown increasingly worse results in the last few years, and 
a meta-analysis failed so show superiority versus both TT 
(80.2% vs 77.4%, 95% CI = 0.94 - 1.13),33 probably due to 
the increasing prevalence of levofloxacin-resistant strains 
of HP in many European countries.14,15
 Importantly, both bismuth-based therapies and the 
newer treatment regimens (hybrid, concomitant and dual), 
are often complex and exhausting, leading to potentially 
lower drug compliance as well as to an increased risks of 
side-effects or overdosing outside clinical trials.34,35 In a 
recent multicentre study,27 patients on hybrid or concomitant 
treatment reported significantly more side-effects than those 
on TT (81 and 79% vs 27%, p = 0.012), while Delchier et 
al36 observed side-effects in 67% of the patients treated with 
bismuth.
 In our work, side-effects were reported by 20% of our 
patients, predominantly dyspepsia, diarrhea and dysgeusia 
with no differences between TT (19.3%) and ST (20.7%). 
Both the incidence and type of reported side-effects are 
consistent with the ones reported in the literature for these 
treatment strategies,27,31 as well as the non-compliance rate 
of 5%.26,27
 Finally, tobacco consumption was significantly 
associated with and lower rates of HP eradication (54.5 
vs 87.8%, p = 0.022). The effect of active smoking in the 
efficacy of HP eradication has been previously reported 
in a meta-analysis (odds-ratio for treatment failure among 
smokers versus non-smokers was 1.95 (95% CI: 1.55 - 
2.45; p < 0.01),37 and on a recent prospective study in a 
Portuguese population15 - suggested explanations for this 
occurrence include a reduction of antibiotic delivery due to a 
decreased gastric blood flow, a decrease in intra-gastric pH 
in smokers, a potentially adjuvant mechanism of nicotine 
to the vacuolating toxin activity of HP, as well as smoking 
being generally associated with poorer compliance.1
 Our study has some limitations: it reports to a small 
sample size, resulting from strict inclusion criteria in a 
prospective, randomized trial; it was an open label study, but 
the risk of bias associated with this methodology was very 
low, as the outcome assessment (13C-UBT) was performed 
by a technician blinded to the treatment strategy. Finally, 
we performed no antibiotic resistance profiling. Although 
resistances to clarithromycin, metronidazol, or even to both, 
are on the rise, significant heterogeneity across countries 
and regions may result in unpredictable eradication rates 
when using standard treatments.14 Antibiotic resistance 
profiling could result in a tailored approach to HP treatment 
and superior primary eradication rates, but at the cost of 
delays in treatment and increased risk of loss to follow-up.
CONCLUSION
 In conclusion, we report for the first time the results 
from a randomized controlled trial for HP eradication in 
naive Portuguese patients comparing two recommended 
regimens by the Maastricht IV Consensus1, finding no 
statistically significant differences between 14-day TT and 
10-day ST. Despite the need for larger prospective studies 
to confirm the most adequate treatment strategy for HP in a 
Southern European country, our results support the use of 
either TT or ST for the first-line eradication of Helicobacter 
pylori.
PROTECTION OF HUMANS AND ANIMALS
 This study was conducted in accordance with the 
principles of the Declaration of Helsinki, ICH Guidelines for 
Good Clinical Practice and in full conformity with relevant 
regulations. Patients provided written informed consent for 
study participation. The study protocol was approved by the 
local ethics committee.
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